SCHEMBL2179130

SCHEMBL2179130

CNC(=O)COC(=O)N1CCN(CCCCc2ccc(Cl)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.65
HRH1 P35367 3/20 0.50
HRH3 Q9Y5N1 2/20 0.50
HRH2 P25021 2/20 0.50
POLB P06746 1/20 0.49
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 2/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
HTR2A P28223 4/20 0.47
SIGMAR1 Q99720 3/20 0.47
OPRM1 P35372 3/20 0.47
ADORA3 P0DMS8 2/20 0.47
HTR7 P34969 2/20 0.47
HTR1A P08908 3/20 0.45
DRD4 P21917 2/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178407 0.94 FAAH (0.62) FAAHHRH1HRH3HRH2POLB
SCHEMBL2175558 0.87 FAAH (0.50) FAAHHRH1HRH2KMT2AHTR2A
SCHEMBL4308368 0.86 HRH3 (0.53) FAAHHRH1HRH3HRH2HTR2A
SCHEMBL2177380 0.84 HRH2 (0.71) FAAHHRH1HRH3HRH2DRD2
SCHEMBL2178351 0.84 FAAH (0.52) FAAHHRH1HRH2KMT2AHTR2A
SCHEMBL2175871 0.84 FAAH (0.52) FAAHHRH1HRH2POLBALDH1A1
SCHEMBL2177424 0.83 SIGMAR1 (0.56) FAAHHRH1HTR2ASIGMAR1OPRM1
SCHEMBL5447729 0.81 FAAH (0.88) FAAHPOLBALDH1A1MAPTLMNA
SCHEMBL2178051 0.81 HRH2 (0.62) FAAHHRH1HRH3HRH2ALDH1A1
SCHEMBL2175549 0.81 MEN1 (0.48) FAAHHRH1HRH2KMT2AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720848-B1 DERIVATIVES OF ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINE- CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2007-12-05 EP claimed
US-7973042-B2 Derivatives of alkylpiperazine- and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors SANOFI-AVENTIS (FR) 2011-07-05 US disclosed
US-20090143365-A1 DERIVATIVES OF ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2009-06-04 US disclosed
US-7482346-B2 Derivatives of alkylpiperazine and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors SANOFI-AVENTIS (FR) 2009-01-27 US disclosed
US-20070027141-A1 DERIVATIVES OF ALKYLPIPERAZINE AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143365-A1 DERIVATIVES OF ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 FAAH 1/4885HRH1 45/4885HRH3 124/4885
US-20070027141-A1 DERIVATIVES OF ALKYLPIPERAZINE AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 FAAH 1/4885HRH1 40/4885HRH3 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.